source
- STAT+: Rare disease drugmakers try to avoid Trump price cutsPlus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.STAT · 10d ago↗ source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace · 10d ago↗ source
- Indian generic drugmaker gets FDA warning over clinical study consentIndian generic drugmaker Alembic Pharmaceuticals has been hit with an FDA warning letter after failing to get informed consent from patients for a clinical study. In a breakaway from typical FDA wa…Endpoints